Thanks, Toby. Recurring revenue for the fourth quarter was $324.7 million, an increase of 15%, with total revenue up 16% from the same period last year. As Toby noted, our sales team had another solid quarter, and we were pleased to come in $5.5 million above the top end of our revenue guidance with the majority of our Q4 beat coming from recurring and other revenue. Adjusted EBITDA for the fourth quarter was $120.2 million or 33.6% margin and exceeded the top end of our guidance by $13.1 million. For fiscal 2024, adjusted EBITDA was $505.6 million or 36% margin, and an increase of 35% on a dollar basis from fiscal 2023, resulting in leverage of 410 basis points. Excluding the impact of interest income on funds held for clients, adjusted EBITDA margin for fiscal 2024 was 30%, reflecting operating leverage of 280 basis points versus fiscal 2023. Additionally, we continue to show strong progress on free cash flow with fiscal 2024 free cash flow margin of 21.8%, up 340 basis points and an increase of 42% on a dollar basis from fiscal 2023. Excluding the impact of interest income on funds held for clients, we drove 170 basis points of operating free cash flow leverage in fiscal 2024 to 14.4% margin. Given our increased profitability and limited remaining NOLs and credits, we expect to become a full cash taxpayer in fiscal 2025, which will create a free cash flow margin headwind in fiscal 2025. But we remain confident in our ability to continue expanding free cash flow margin in the coming years. We continue to make significant investments in research and development and to understand our overall investment in R&D, it is important to combine both what we expense and what we capitalize. On a combined non-GAAP basis, total R&D investments were 14.6% of revenue in the fourth quarter and on a full year basis, total R&D investments were 14.2% of revenue. On a dollar basis, our year-over-year investment in total R&D increased by 18% in fiscal 2024 when compared to fiscal 2023. We continue to believe our investments in R&D provide us with valuable product differentiation and the ability to drive future growth as we deliver the most modern platform in the industry. On a non-GAAP basis, sales and marketing expenses were 22.5% of revenue in the fourth quarter and 21.2% of revenue in fiscal 2024. On a non-GAAP basis, G&A costs were 9.6% of revenue in the fourth quarter versus 10.7% in the same period last year. Full year G&A costs were 9.3% of revenue as compared to 11% in fiscal 2023 representing 170 basis points of leverage, and we remain focused on consistently leveraging G&A expenses on an annual basis. Briefly covering our GAAP results. For Q4, gross profit was $240.4 million, operating income was $62.9 million and net income was $48.8 million. For the full year, gross profit was $960.8 million, operating income was $260.1 million and net income was $206.8 million. In regard to funds held for clients and interest income, our average daily balance of client funds was $2.8 billion in Q4 and $2.6 billion for fiscal 2024. We are estimating the average daily balance will be approximately $2.5 billion in Q1 of fiscal 2025 with an average annual yield of approximately 450 basis points, representing approximately $28 million of interest income on client health funds in Q1. On a full year basis, we are estimating the average daily balance will be $2.75 billion in fiscal 2025 with an average yield of approximately 390 basis points, representing approximately $107 million of interest income on funds held for clients. In regards to interest rates, our guidance assumes 425 [ph] basis point rate cuts during fiscal 2025 with the cut assumed in September, November, March and May reflected in guidance. Additionally, given the confidence we have in our business and our strong cash flows, we repurchased approximately 1.1 million shares of common stock at an average price of $142.82 per share for $150 million in aggregate repurchases during Q4. As a reminder, we have $350 million remaining under our share repurchase program. We also closed Q4 with $401.8 million in cash and cash equivalents on our balance sheet. In fiscal 2024, we also drove 200 basis points of leverage in stock-based compensation expense. And in fiscal 2025, we expect to drive continued leverage in stock-based compensation towards our target of less than 10% of revenue and are committed to driving incremental leverage and stock-based comp annually going forward. Finally, I’d like to provide our financial guidance for Q1 and full fiscal 2025, which includes the impact of the 425 basis point interest rate cuts in fiscal 2025, as mentioned earlier, and roughly flat workforce levels in fiscal 2025 versus fiscal 2024. For the first quarter of fiscal 2025, recurring and other revenue is expected to be in the range of $325.5 million to $330.5 million or approximately 12.5% growth over first quarter of fiscal 2024 recurring and other revenue. And total revenue is expected to be in the range of $353.5 million to $358.5 million or approximately 12.1% growth over first quarter fiscal 2024 total revenue. Adjusted EBITDA is expected to be in the range of $116.5 million to $120.5 million. In adjusted EBITDA, excluding interest income on funds held for clients is expected to be in the range of $88.5 million to $92.5 million, which represents approximately 60 basis points of leverage over Q1 of fiscal 2024. And for fiscal year 2025, recurring and other revenue is expected to be in the range of $1.405 billion to $1.420 billion or approximately 10.2% growth over fiscal 2024 recurring and other revenue. Total revenue is expected to be in the range of $1.512 billion to $1.527 billion or approximately 8.3% growth over fiscal 2024. Adjusted EBITDA is expected to be in the range of $533 million to $543 million. Adjusted EBITDA, excluding interest income on funds held for clients is expected to be in the range of $426 million to $436 million, which represents approximately 50 basis points of leverage over fiscal 2024. Despite the macro headwinds we faced in 2024, we’re pleased to finish the year with 19% total revenue growth, 17% recurring revenue growth and adjusted EBITDA margin of 36% and a rule of 55 overall performance. As we kick off fiscal 2025, we remain confident in our differentiated value proposition, go-to-market strategy, operational strength and product road map, and we have a high level of confidence in our ability to continue driving durable revenue growth and increasing margins as we execute against our multiyear goal of achieving $2 billion in total revenue. I would now like to turn the call over to Steve for final remarks.